文献速递胸部肿瘤

克唑替尼对ALK阳性晚期非小细胞肺癌患者的肾脏影响

Renal Effects of Crizotinib in Patients With ALK-Positive Advanced NSCLC.
PubMed 文献 · J Thorac Oncol · 2019-02-26

该研究回顾性分析四项试验中克唑替尼对ALK阳性晚期NSCLC患者血清肌酐和基于肌酐的eGFR的影响。结果显示肌酐中位值从基线0.79 mg/dL升至治疗2周后0.93 mg/dL,eGFR中位值从基线96.42降至第2周80.23 mL/min/1.73 m2,长期治疗无明显累积效应且停药后多可逆。

要点

  • 克唑替尼治疗后血清肌酐中位值从基线0.79 mg/dL升至2周时0.93 mg/dL,中位增幅21.2%。
  • eGFR中位值从基线96.42降至第2周80.23、第12周78.06、第104周75.45 mL/min/1.73 m2。
  • 12.6%患者eGFR分级从基线≤3a级(≥45)转为≥3b级(<45 mL/min/1.73 m2)。

核心结论

  • 克唑替尼导致基于肌酐的肾功能估计值下降,主要发生在治疗前2周,长期治疗无明显累积效应,停药后变化多可逆,可能与肌酐分泌影响而非真正肾毒性有关。

研究设计与样本

  • 回顾性分析四项试验(NCT00585195、NCT00932451、NCT00932893、NCT01154140)中ALK阳性晚期NSCLC患者,评估克唑替尼对血清肌酐和基于CKD-EPI肌酐方程的eGFR的影响。

主要发现

  • 血清肌酐中位值从基线0.79 mg/dL升至治疗2周后0.93 mg/dL(中位较基线增幅21.2%),第12周0.96 mg/dL至第104周1.00 mg/dL保持稳定,末次给药后28天降至0.90 mg/dL(中位较基线增幅13.1%)。
  • eGFR中位值随时间下降:基线96.42、第2周80.23、第12周78.06、第104周75.45 mL/min/1.73 m2,末次给药后28天升至83.02 mL/min/1.73 m2。
  • eGFR中位较基线降幅在第2周为14.9%、第12周为17.0%、末次给药后28天为10.4%。
  • 总体12.6%患者eGFR分级从基线≤3a级(≥45 mL/min/1.73 m2)转为基线后≥3b级(<45 mL/min/1.73 m2)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: We retrospectively analyzed the effects of crizotinib on serum creatinine and creatinine-based estimated glomerular filtration rate (eGFR) in patients with anaplastic lymphoma kinase-positive advanced NSCLC across four trials (NCT00585195, NCT00932451, NCT00932893, and NCT01154140). METHODS: Changes from baseline data in serum creatinine and eGFR, calculated using the Chronic Kidney Disease Epidemiology Collaboration creatinine-based equation, were assessed over time. eGFR was graded using standard chronic kidney disease criteria. RESULTS: Median serum creatinine increased from 0.79 mg/dL at baseline to 0.93 mg/dL after 2 weeks of treatment (median percentage increase from baseline, 21.2%), was stable from week 12 (0.96 mg/dL) to week 104 (1.00 mg/dL), and decreased to 0.90 mg/dL at 28 days after last dose (median percentage increase from baseline, 13.1%). Median eGFR decreased over time (96.42, 80.23, 78.06 and 75.45 mL/min/1.73 m2 at baseline, week 2, week 12, and week 104, respectively) and increased to 83.02 mL/min/1.73 m2 at 28 days after the last dose. Median percentage decrease from baseline was 14.9%, 17.0%, and 10.4% at week 2, week 12, and 28 days after last dose of crizotinib, respectively. Overall, 12.6% of patients had a shift from eGFR grade less than or equal to 3a (≥45 mL/min/1.73 m2) at baseline to greater than or equal to 3b (<45 mL/min/1.73 m2) post-baseline. CONCLUSIONS: Crizotinib resulted in a decline in creatinine-based estimates of renal function mostly over the first 2 weeks of treatment. However, there was minimal evidence of cumulative effects with prolonged treatment and these changes were largely reversible following treatment discontinuation, consistent with previous reports suggesting this may be predominantly an effect on creatinine secretion as opposed to true nephrotoxicity.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Camidge DR, Kim EE, Usari T, et al. Renal Effects of Crizotinib in Patients With ALK-Positive Advanced NSCLC. J Thorac Oncol. 2019. PMID: 30822515. doi:10.1016/j.jtho.2019.02.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。